Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study (PharmacoEconomics, (2021), 10.1007/s40273-021-01026-5)

Becky Pennington*, Abualbishr Alshreef, Laura Flight, Andrew Metry, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana C. Vasconcelos, Caroline Murphy, Joanna Kelly, Yit Yang, Andrew Lotery, Michael Williams, John Brazier

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study,written by Becky Pennington, Abualbishr Alshreef, Laura Flight, Andrew Metry, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost , Joana C. Vasconcelos, Caroline Murphy, Joanna Kelly , Yit Yang, Andrew Lotery, Michael Williams and John Brazier was published under the incorrect Creative Commons (CC) license (CC-BY-NC). The correct license is CC-BY. Open access for this paper was funded by the NIHR HTA programme through Moorfields Eye Hospital. 

Original languageEnglish
Article number1099
Number of pages1
JournalPharmacoEconomics
Volume39
DOIs
Publication statusAccepted - 2021

Bibliographical note

Funding Information:
The article Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study,written by Becky Pennington, Abualbishr Alshreef, Laura Flight, Andrew Metry, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost , Joana C. Vasconcelos, Caroline Murphy, Joanna Kelly , Yit Yang, Andrew Lotery, Michael Williams and John Brazier was published under the incorrect Creative Commons (CC) license (CC-BY-NC). The correct license is CC-BY. Open access for this paper was funded by the NIHR HTA programme through Moorfields Eye Hospital.

Publisher Copyright:
© The Author(s) 2021

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint

Dive into the research topics of 'Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study (PharmacoEconomics, (2021), 10.1007/s40273-021-01026-5)'. Together they form a unique fingerprint.

Cite this